Understanding the polypharmacological anticancer effects of Xiao Chai Hu Tang via a computational pharmacological model
- PMID: 24926384
- PMCID: PMC4043560
- DOI: 10.3892/etm.2014.1660
Understanding the polypharmacological anticancer effects of Xiao Chai Hu Tang via a computational pharmacological model
Abstract
Xiao Chai Hu Tang (XCHT), a traditional herbal formula, is widely administered as a cancer treatment. However, the underlying molecular mechanisms of its anticancer effects are not fully understood. In the present study, a computational pharmacological model that combined chemical space mapping, molecular docking and network analysis was employed to predict which chemical compounds in XCHT are potential inhibitors of cancer-associated targets, and to establish a compound-target (C-T) network and compound-compound (C-C) association network. The identified compounds from XCHT demonstrated diversity in chemical space. Furthermore, they occupied regions of chemical space that were the same, or close to, those occupied by drug or drug-like compounds that are associated with cancer, according to the Therapeutic Targets Database. The analysis of the molecular docking and the C-T network demonstrated that the potential inhibitors possessed the properties of promiscuous drugs and combination therapies. The C-C network was classified into four clusters and the different clusters contained various multi-compound combinations that acted on different targets. The study indicated that XCHT has a polypharmacological role in treating cancer and the potential inhibitory components of XCHT require further investigation as potential therapeutic strategies for cancer patients.
Keywords: Xiao Chai Hu Tang; cancer; computational pharmacology; polypharmacology.
Figures
References
-
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917. - PubMed
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
-
- Carney DN, Hansen HH. Non-small-cell lung cancer - stalemate or progress? N Engl J Med. 2000;343:1261–1262. - PubMed
-
- Bröker LE, Giaccone G. The role of new agents in the treatment of non-small cell lung cancer. Eur J Cancer. 2002;38:2347–2361. - PubMed
-
- Yang CS, Wang H, Hu B. Combination of chemopreventive agents in nanoparticles for cancer prevention. Cancer Prev Res (Phila) 2013;6:1011–1014. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources